Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -6 of 6 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:

Last Modified: 7/1/1997


1.		Phase III Study of IL-2 vs IL-2 plus PEG-IL-2 in Patients with Metastatic Renal Cell Carcinoma (Summary Last Modified 07/97)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				16 and over				NCI				NCI-90-C-85C NCI-T90-0053N, T90-0053

Last Modified: 7/1/1997


2.		Phase I/II Study of Intratumoral PEG-IL-2 in Patients with Clinical Stage B2/C Prostate Cancer Undergoing Radical Prostatectomy (Summary Last Modified 07/97)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 and over				Other				UCLA-HSPC-9402069 NCI-V94-0537

Last Modified: 5/1/1991


3.		Phase II Multicenter Evaluation of Adjuvant Recombinant PEG Human Interleukin-2 Given as a Weekly Bolus to Adult Patients with AML in Remission After First Relapse (Summary Last Modified 05/91)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 to 75								AECM-9002042 NCI-V90-0035

Last Modified: 8/20/2007


4.		Phase II Study of PEG-IL-2 in Patients with Advanced Renal Cell Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over								UNM-0989C NCI-V89-0215

Last Modified: 6/1/1997


5.		Phase I Study of Polyethylene Glycol-Modified Recombinant Human Interleukin-2 in Patients with Metastatic Cancer (Summary Last Modified 06/97)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				16 and over				NCI				NCI-89-C-131B NCI-T89-0085N, T89-0085

Last Modified: 8/1/1990


6.		Phase I Study of PEG-IL-2 in Patients with Cytogenetic or Clinical Relapse of CML Following Allogeneic Marrow Transplantation (Summary Last Modified 08/90)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				18 to physiologic 70								MSKCC-90022 NCI-V90-0072

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute